Leflunomide, HCQ Combo Effects Validated in Sjögren Disease
BARCELONA, Spain — In the treatment of primary Sjögren disease, the use of leflunomide (LEF) and hydroxychloroquine (HCQ) in combination was associated with a greater reduction in disease activity than placebo, according to new trial results reported at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting.
In the randomized controlled RepurpSS-II trial, the LEF-HCQ combination produced a mean decrease in EULAR Sjögren syndrome disease activity index (ESSDAI) score of 4.13 points ( P = .001) relative to placebo after 24 weeks of treatment.
There were also greater reductions in serum immunoglobulin G, rheumatoid factor, and complement component 4 with the combination than with placebo.
However, there were no differences between the groups in terms of patients' symptoms as measured by the EULAR Sjögren syndrome patient reported index (ESSPRI) or its separate components.
There were also no differences between the groups in improving dryness as measured using the Schirmer and unstimulated saliva tests.
Confirmatory Trial
Wing-Yi Wong, MD
'The major challenge in this disease is the lack of standard treatments, despite the need,' said Wing-Yi Wong, MD, a PhD student at University Medical Center Utrecht, Utrecht, the Netherlands, who presented the findings as a late-breaking abstract.
'Many trials in the past 40 years have failed to show clinical efficacy,' Wong added. One of the few trials that had proven promising previously, however, was the RepurpSS-I trial, which had tested a combination of LEF at a dose of 20 mg/d and HCQ at a dose of 400 mg/d given for 24 weeks vs placebo.
RepurpSS-II was set up to confirm the findings of RepurpSS-I. Published in The Lancet Rheumatology in 2020, RepurpSS-I had shown that LEF-HCQ reduced ESSDAI a mean of 4.29 points more than that with placebo.
Trial Designs and RepurpSS-II Population
RepurpSS-I was a phase 2a trial, and RepurpSS-II was a phase b2 trial. Entry criteria were similar for both trials: Primary Sjögren disease diagnosis, an ESSDAI ≥ 5, and no significant comorbidities. Women of a child-bearing age also had to be taking reliable contraception.
Both RepurpSS trials included 24-week double-blind treatment phases, with RepurpSS-II adding a single-arm crossover extension for a further 24 weeks.
A total of 37 people with primary Sjögren disease had been screened for inclusion in RepurpSS-I, 29 were included, 21 of whom were treated with the LEF-HCQ combination and eight with placebo.
For RepurpSS-II, 85 of 233 people who were considered for inclusion were screened, and 46 were included in the trial. Of these, 21 were treated with LEF-HCQ and 25 with placebo.
Among the reasons for not screening or including more people in RepurpSS-II were comorbidities; current or recent treatment with LEF, HCQ, or other disease-modifying antirheumatic drugs; and not meeting other entry criteria.
Participants in the LEF-HCQ and placebo groups of RepurpSS-II were demographically similar: The mean age was 55 years; 90.5% and 96.0%, respectively, were women; and the mean disease durations were 6.5 years and 10.0 years, respectively.
Mean ESSDAI scores at baseline were 9.52 in the LEF-HCQ group and 9.88 in the placebo group, and mean ESSPRI scores were 7.00 and 6.83, respectively.
Other Findings
Exploratory analyses using the Sjögren's Tool for Assessing Response (STAR) and the Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) also favored LEF-HCQ.
'STAR and CRESS scores are two novel composite endpoints that includes patient-reported outcomes together with objective measures of dryness alongside the clinical ESSDAI,' Wong said.
She reported that there was a 'significantly higher percentage of responders' in the LEF-HCQ group using both measures vs placebo.
Adverse event rates were similar between groups: A total of 58 events occurred in the LEF-HCQ group and 57 in the placebo group. Most of these events were considered as mild (77.6% for LEF-HCQ and 66.7% for placebo), with gastrointestinal discomfort and respiratory infections among the most commonly reported.
Two severe adverse events occurred, one in each group, and were deemed unrelated to the study treatment. The one in the LEF-HCQ group was a non-ST elevation myocardial infarction, and the one in the placebo group was an allergic reaction to antibiotic treatment.
A total of 14 patients in the LEF-HCQ group completed the double-blind phase, and nine chose to enter the 24-week, open-label extension. Although completed, results of this phase are pending.
'Overall, the combination treatment was well tolerated, and leflunomide-hydroxychloroquine is realistic treatment option, which is affordable, accessible, and widely available,' Wong concluded.
This study was funded by the Dutch independent government body ZonMw . Wong and fellow investigators for the RepurpSS-II study had no relevant conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Infections Affect Over Half of EU Long-Term Care Residents
TOPLINE: In a 12-month longitudinal analysis of long-term care facility residents across European countries, 57% experienced at least one healthcare-associated infection (HAI), with respiratory tract and urinary tract infections being the most common and leading to significant hospitalisations and deaths. METHODOLOGY: Researchers conducted a longitudinal cohort study across nine European countries to examine the incidence of HAIs and their associated hospitalisations and mortality in residents of long-term care facilities. They analysed 3029 residents (mean age, 80.9 years; 68% women) who stayed in their facilities, including general nursing homes, residential homes, and mixed facilities, throughout the 12-month study period. Data were collected via standardised questionnaires covering facility characteristics, resident demographics, and details about HAIs; infections acquired within the facility or during temporary discharge were included. The primary outcome was the incidence of HAIs; secondary outcomes included HAI-related hospitalisations (occurring between the onset and resolution) and HAI-associated deaths. TAKEAWAY: Overall, 57% of the residents experienced at least one HAI during follow-up, with an incidence rate of 1.8 (95% CI, 0.9-3.3) per 1000 resident days. Respiratory tract infections were the most common HAIs (28.9%; 95% CI, 27.3-30.5), followed by urinary tract infections (18.7%; 95% CI, 17.2-20.3) and COVID-19 (17.6%; 95% CI, 16.5-18.8). The incidence of HAI-related hospitalisations was 0.09 (95% CI, 0.05-0.21) per 1000 resident days; the highest incidence was observed for respiratory tract infections, followed by urinary tract infections and COVID-19. Overall, 4.5% of HAIs were fatal, and respiratory tract infections were the most common cause, accounting for 2.3% of deaths. IN PRACTICE: "Nevertheless, these data shed important light on a highly relevant topic within a health-care setting that is often neglected," the authors of a commentary wrote. "There is a need for ongoing surveillance of infections, work to validate surveillance definitions, and more epidemiological data (eg, pathogen-specific burden, contribution of outbreak vs sporadic infections, and added burden of antimicrobial resistance)," they added. SOURCE: This study was led by Enrico Ricchizzi, PhD, Settore Innovazione nei Servizi Sanitari e Sociali, Regione Emilia-Romagna, Bologna, Italy. It was published online on June 16, 2025, in The Lancet Infectious Diseases. LIMITATIONS: This study was limited by variability in implementation of the survey across participating facilities and the biased selection of long-term care facilities. The diverse types of facilities included introduced heterogeneity. Moreover, this study did not assess the effect of infection prevention measures or available local resources at each facility. DISCLOSURES: This study was supported by the European Centre for Disease Prevention and Control. The authors declared having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
Scientists discover surprising cause for rapid increase in bedbug population: 'The bugs spread with them'
Scientists have discovered a surprising connection between the rise in civilizations and a subsequent increase in bedbug populations. Though they're not known to transmit diseases, the pests can contribute to sleep and mental health issues. As the Guardian reported, a new study by an international team of researchers found that bedbugs could likely be "the first urban pest insect," as their numbers exploded when humans began expanding across the globe and building cities. Dr. Warren Booth, an urban entomologist at Virginia Tech and a co-author of the research, said that when human settlements first emerged around 10,000 years ago, it created the ideal conditions for the blood-sucking parasites to thrive. "When we started to live in cities, we brought all these people together, and they all had their own bedbugs with them," Booth said. "And then, as civilisation spread across the world, the bugs spread with them to the point where they're now ubiquitous in human society." For the study, which was published in Biology Letters, the team compared the genetic material of 19 bedbugs from the Czech Republic and discovered that populations associated with both bats and humans — two common hosts for bedbugs — started declining in the midst of the last ice age, about 45,000 years ago. However, their populations experienced a "dramatic" rise around 8,000 years ago, shortly after humans migrated into big cities. While bedbugs are not generally considered to be harmful, they can cause discomfort and annoyance, especially if you're dealing with an infestation. Plus, some people experience minor symptoms, including itching and irritation, red, swollen bumps, and even allergic reactions that require treatment. Not to mention, knowing you have bedbugs crawling around your sheets can lead to insomnia and poor well-being. Having to replace bedding and potentially seek professional help to eradicate them is also a major hassle. However, the elephant in the room is that soaring bedbug numbers and the shifting climate have more to do with each other than you'd think. Warmer temperatures and higher humidity levels can accelerate bedbug life cycles and lead to more frequent reproduction. Additionally, a hotter climate provides the ideal conditions for pests to expand their ranges and colonize areas they previously could not survive in. Changes in the climate can also disrupt natural predators or competitors of bedbugs, further contributing to their successful reproduction. While bedbugs don't directly harm the planet, the need to control or eliminate them often involves the use of pesticides, which can damage ecosystems and hurt wildlife. In the grand scheme of things, bedbugs may be relatively harmless compared to other pests, but bugs such as mosquitoes, ticks, and fleas are contributing to an alarming rise in vector-borne illnesses — including malaria, Lyme disease, and typhus — around the globe. Do you worry about getting diseases from bug bites? Absolutely Only when I'm camping or hiking Not really Never Click your choice to see results and speak your mind. Prevention is the best cure, as they say, so regular cleaning and decluttering around your home will help keep the bedbugs at bay. If you have an infestation, make sure to thoroughly wash and dry bedding on high heat, use steam or heat treatments, or call for professional help if necessary. Keeping your home clean with natural cleaning products such as baking soda and vinegar is also a simple, affordable solution to prevent (or at least lessen) the likelihood of attracting bedbugs. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Yahoo
an hour ago
- Yahoo
The biggest challenge facing Wes Streeting over scandalous state of maternity services
This was a powerful speech from the health secretary who is clearly troubled by the scandalous state of maternity services in this country. Wes Streeting has spent the past year meeting bereaved families who have been failed by the NHS. He said he "was kept up at night" after listening to their harrowing testimonies. Announcing a national investigation into NHS maternity services, this review is modelled on the Darzi report into the NHS, commissioned by the health secretary almost as soon as he came into office. It . The terms of reference for the investigation will be known by July. The actual report is expected to be published by Christmas. Mr Streeting accepts this is an ambitious timeline but is driven by the fear that mothers and babies are still being failed and he does not want "any deaths on his watch". And he has not ruled out a future public inquiry, which is what the bereaved families have been demanding. The biggest challenge for the health secretary will be to change the culture within maternity units. This has been identified as one of the biggest issues in previous reports by Bill Kirkup and Donna Ockenden. It's why, Mr Streeting said, he chose to make his announcement at the Royal College of Obstetricians and Gynaecologists' World Congress Day. What he said would have made for uncomfortable listening for some delegates but he needs them on board to deliver on his promise to make maternity and neonatal care safe. Read more from Sky News: The health secretary clearly has empathy. He has listened to the families torn apart by maternity failings. But if there is any criticism of his action, it is that it could have been taken sooner, up to six months ago. The failures across maternity services up and down the country have been known about for a long time.
